NL-OMON56701尚未招募3 期
ong-term follow-up of patients with spinal muscular atrophy Treated with OAV101 IT or OAV101 IV in Clinical Trials - OAV101
适应症
试验速览
- 阶段
- 3 期
- 状态
- 尚未招募
- 发起方
- ovartis
- 入组人数
- 2
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Observational
入排标准
- 年龄范围
- 2 至 64（—）
入选标准
- •Participants eligible for inclusion in this study must meet all of the
- •following criteria:
- •1. Participated in an OAV101 clinical trial.
- •2. Written informed consent must be obtained before any assessment is performed.
- •3. Patient/Parent/legal guardian willing and able to comply with study
- •procedures.
排除标准
- •There are no specific exclusion criteria for this study.
研究者
相似试验
进行中（未招募）
1 期
ong-term follow-up of patients with spinal muscular atrophy Treated with OAV101 in Clinical TrialsMedDRA version: 20.1Level: PTClassification code 10041582Term: Spinal muscular atrophySystem Organ Class: 10010331 - Congenital, familial and genetic disordersSpinal Muscular AtrophyEUCTR2021-006781-21-BEovartis Pharma AG260
进行中（未招募）
1 期
ong-term follow-up of patients with spinal muscular atrophy Treated with OAV101 in Clinical TrialsMedDRA version: 20.1Level: PTClassification code 10041582Term: Spinal muscular atrophySystem Organ Class: 10010331 - Congenital, familial and genetic disordersSpinal Muscular AtrophyEUCTR2021-006781-21-FRovartis Pharma AG260
进行中（未招募）
1 期
ong-term follow-up of patients with spinal muscular atrophy Treated with OAV101 in Clinical TrialsMedDRA version: 20.1Level: PTClassification code 10041582Term: Spinal muscular atrophySystem Organ Class: 10010331 - Congenital, familial and genetic disordersSpinal Muscular AtrophyEUCTR2021-006781-21-DKovartis Pharma AG260
进行中（未招募）
1 期
ong-term follow-up of patients with spinal muscular atrophy Treated with OAV101 IT or OAV101 IV in Clinical TrialsMedDRA version: 20.1Level: PTClassification code: 10041582Term: Spinal muscular atrophy Class: 100000004850Spinal Muscular AtrophyCTIS2024-511707-42-00ovartis Pharma AG160
尚未招募
3 期
ong-term Follow-up of Patients with Spinal Muscular Atrophy Treated with OAV101 in Clinical trialsSpinal Muscular AtrophyJPRN-jRCT2033230642Hirano Takamitsu4